Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 8×
“Five of the studies were conducted in China (17-19, 21, 22) and Egypt (11, 16, 20, 23, 24), while the others were conducted in Iran (14, 15), Korea (12) and Sweden (13) (Table 1).”
BackgroundMethodResultInfluentialZhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 8×
“Five of the studies were conducted in China (17-19, 21, 22) and Egypt (11, 16, 20, 23, 24), while the others were conducted in Iran (14, 15), Korea (12) and Sweden (13) (Table 1).”
BackgroundMethodResultInfluentialAmer, M.-E. M., El-Sayed, S. Z., El-Kheir, W. A., Gabr, H., Gomaa, A. A., El-Noomani, N., & Hegazy, M. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283488b00 · Cited by 180
El-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179
Wang, L., Han, Q., Chen, H., Wang, K., Shan, G.-L., Kong, F., Yang, Y.-J., Li, Y.-Z., Zhang, X., Dong, F., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0500 · Cited by 89
Amin, M. A., Sabry, D., Rashed, L. A., Aref, W. M., el‐Ghobary, M. A., Farhan, M. S., Fouad, H. A., & Youssef, Y. A. (2013) · Clinical Transplantation · doi:10.1111/ctr.12179 · Cited by 88 · cited 11×
“Five of the studies were conducted in China (17-19, 21, 22) and Egypt (11, 16, 20, 23, 24), while the others were conducted in Iran (14, 15), Korea (12) and Sweden (13) (Table 1).”
BackgroundMethodResultInfluential
Cited by
Kim, G., Kang, S. H., Kim, M. Y., & Baik, S. K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186990 · Cited by 369
Self-citationSuk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
“Other concerns include the fibrosis-inducing and tumorpromoting capacity of MSCs.(29) The current study, a randomized phase 2 trial following a previous study, demonstrated the efficacy and safety of autologous BM-MSC transplantation (one-time or twotime hepatic arterial injection of 5 × 10 7 BM-MSCs) for patients wit…”
BackgroundInfluentialSelf-citationMardpour, S., Ghanian, M. H., Sadeghi-abandansari, H., Mardpour, S., Nazari, A., Shekari, F., & Baharvand, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b10126 · Cited by 211
Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives
Kang, S. H., Kim, M. Y., Eom, Y. W., & Baik, S. K. (2020) · Gut and Liver · doi:10.5009/gnl18412 · Cited by 78
“Of these cell types, MSCs have been shown to have the advantages of being obtained relatively easily and possessing low immunogenicity.(6) They have self-renewal ability and can differentiate into cells of various lineages, including osteoblasts, adipocytes, and chondrocytes.”
BackgroundSelf-citationFathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T. (2020) · Molecules · doi:10.3390/molecules25020348 · Cited by 44
“uring the past fe years, researchers have reported that S s counter and exert therapeutic benefits against hepatic fibrosis [18,19].”
Background
Metadata
- Authors
- Kim, G., Eom, Y. W., Baik, S. K., Shin, Y., Lim, Y. L., Kim, M. Y., Kwon, S. O., & Chang, S. J.
- Venue
- Journal of Korean Medical Science
- Publisher
- XMLink
- Published
- 2015
- Volume
- 30
- Issue
- 10
- Pages
- 1405
- ISSN
- 1011-8934 (ISSN-L)
- 1598-6357
- OpenAlex
- W2156119394
- Cited by
- 54
- References
- 6
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.3346/jkms.2015.30.10.1405
- The paper
- Kim, G., Eom, Y. W., Baik, S. K., Shin, Y., Lim, Y. L., Kim, M. Y., Kwon, S. O., & Chang, S. J. (2015). Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2015.30.10.1405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.